Search: onr:"swepub:oai:DiVA.org:uu-197809" >
Reduced intensity c...
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
-
Warlick, Erica (author)
-
Ahn, Kwang Woo (author)
-
Pedersen, Tanya L (author)
-
show more...
-
Artz, Andrew (author)
-
de Lima, Marcos (author)
-
Pulsipher, Michael (author)
-
Akpek, Gorgun (author)
-
Aljurf, Mahmoud (author)
-
Cahn, Jean-Yves (author)
-
Cairo, Mitchell (author)
-
Chen, Yi-Bin (author)
-
Cooper, Brenda (author)
-
Deol, Abhinav (author)
-
Giralt, Sergio (author)
-
Gupta, Vikas (author)
-
Khoury, H Jean (author)
-
Kohrt, Holbrook (author)
-
Lazarus, Hillard M (author)
-
Lewis, Ian (author)
-
- Olsson, Richard (author)
- Karolinska Institutet
-
Pidala, Joseph (author)
-
Savani, Bipin N (author)
-
Seftel, Matthew (author)
-
Socié, Gerard (author)
-
Tallman, Martin (author)
-
Ustun, Celaettin (author)
-
Vij, Ravi (author)
-
Vindeløv, Lars (author)
-
Weisdorf, Daniel (author)
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2012
- 2012
- English.
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 119:17, s. 4083-4090
- Related links:
-
https://ashpublicati...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Warlick, Erica
-
Ahn, Kwang Woo
-
Pedersen, Tanya ...
-
Artz, Andrew
-
de Lima, Marcos
-
Pulsipher, Micha ...
-
show more...
-
Akpek, Gorgun
-
Aljurf, Mahmoud
-
Cahn, Jean-Yves
-
Cairo, Mitchell
-
Chen, Yi-Bin
-
Cooper, Brenda
-
Deol, Abhinav
-
Giralt, Sergio
-
Gupta, Vikas
-
Khoury, H Jean
-
Kohrt, Holbrook
-
Lazarus, Hillard ...
-
Lewis, Ian
-
Olsson, Richard
-
Pidala, Joseph
-
Savani, Bipin N
-
Seftel, Matthew
-
Socié, Gerard
-
Tallman, Martin
-
Ustun, Celaettin
-
Vij, Ravi
-
Vindeløv, Lars
-
Weisdorf, Daniel
-
show less...
- Articles in the publication
-
Blood
- By the university
-
Uppsala University
-
Karolinska Institutet